Video

Dr. Karlan Discusses AMG 386 in Recurrent Ovarian Cancer

Author(s):

Beth Y. Karlan MD

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Discusses AMG 386 in Recurrent Ovarian Cancer

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH
Related Content
Roopal Thakkar, MD
September 20th 2024

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

FDA
September 16th 2024

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Shibani Nicum, BSc (Hons), MBChB, MRCP, DPhil
September 15th 2024

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

US FDA
August 29th 2024

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers